All In Biotech

Drug Trial Radar · NCT05021835

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

ZEUS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease and Systemic Inflammation

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,385 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,385

Actual

Start

Aug 30, 2021

Primary completion

Jun 9, 2026

Study completion Jun 9, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (a dummy medicine which has no effect on the body). This is known as the study medicine. Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe. Participants will get the study medicine in a pre filled syringe. Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits. Participants will have their heart examined using sound waves (echocardiography) and electrodes (electrocardiogram). Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Conditions

  • Cardiovascular Risk
  • Chronic Kidney Disease
  • Inflammation

Interventions

  • Ziltivekimab BDrug

    Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

  • Ziltivekimab CDrug

    Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

  • Placebo (Ziltivekimab B)Drug

    Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

  • Placebo (Ziltivekimab C)Drug

    Administered subcutaneously (s.c., under skin) once-monthly added to standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first occurrence of 3-point Major Adverse Cardiovascular Event (MACE), a composite endpoint consisting of: Cardiovascular (CV) death, non-fatal Myocardial Infarction (MI) and non-fatal strokeTime frame: From randomisation (month 0) to end-of-study (up to 48 months)

Locations

1,073 sites in 38 countries. Site status is shown where the registry gives one.

  • Uni of Alabama at Birmingham

    Birmingham, Alabama

  • Chambliss Clinical Trials LLC

    Montgomery, Alabama

  • Lenzmeier Fam Med CCT Research

    Glendale, Arizona

  • Aventiv Research Inc.

    Mesa, Arizona

  • Univ of Arkansas Med Sciences

    Little Rock, Arkansas

  • Unity Health-Searcy Medical Center

    Searcy, Arkansas

  • National Heart Institute Cal

    Beverly Hills, California

  • California Inst Of Renal Res

    Chula Vista, California

  • California Institute of Renal Research #10

    Chula Vista, California

  • Valley Clinical Trials

    Covina, California

  • Valiance Clinical Research

    Huntington Park, California

  • Scripps Wht Diab Inst La Jolla

    La Jolla, California

  • Balboa Nephro Med Gr Inc LaMes

    La Mesa, California

  • First Valley Medical Group

    Lancaster, California

  • VA Loma Linda Hlthcr Sys

    Loma Linda, California

  • Pacific Clinical Studies

    Los Alamitos, California

  • Angel City Research, Inc.

    Los Angeles, California

  • North America Research Institute

    Lynwood, California

  • Hoag Medical Group

    Newport Beach, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Riverside Nephrology Physicians

    Riverside, California

  • N America Res Inst - San Dimas

    San Dimas, California

  • Lundquist Inst-Biomed Innovtn

    Torrance, California

  • Denver Health Outpatient Medical Center

    Denver, Colorado

  • Bridgeport Hospital

    Bridgeport, Connecticut

  • VA-Connecticut (VACHS)

    West Haven, Connecticut

  • George Washington Uni Med

    Washington D.C., District of Columbia

  • Excel Med Ctr Clinical Trials

    Boca Raton, Florida

  • Florida Premier Cardiology

    Boynton Beach, Florida

  • Innovative Research of W FL

    Clearwater, Florida

  • Northeast Research Institute

    Fleming Island, Florida

  • Integrative Research Assoc Inc

    Fort Lauderdale, Florida

  • Elixia Pines

    Hollywood, Florida

  • Encore Medical Research LLC

    Hollywood, Florida

  • Northeast Research Institute

    Jacksonville, Florida

  • Est Cst Inst for Rsrch,Jksnvil

    Jacksonville, Florida

  • Baptist Heart Specialists

    Jacksonville, Florida

  • Clinical Research of Cent FL

    Lakeland, Florida

  • Pharmax Research Clinic

    Miami, Florida

Showing 40 of 1,073 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.